May 28, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced a strategic partnership with Densitas, Inc., a global leader in operational AI solutions for breast cancer screening. The partnership enables breast imaging centers and radiologists to provide end-to-end breast health care that ensures every aspect of a woman’s breast health journey is addressed, starting from the first step of quality screening mammograms and extending through breast cancer detection, breast density assessment, and a comprehensive evaluation of breast cancer risk.
"We are thrilled to announce this strategic collaboration with Densitas to offer physicians and patients a more comprehensive, holistic approach to precision breast health care,” said Dana Brown, President and CEO of iCAD. “By combining Densitas’ AI-powered intelliMammo platform with iCAD’s AI-powered ProFound Breast Health Suite, we are transforming early breast cancer detection and intervention.”
Densitas offers a robust and comprehensive mammography quality assurance platform, comprised of intelliMammo and intelliMaven. IntelliMammo is built on deep learning and machine learning algorithms that assess clinical image quality and breast density that are the foundation for advanced analytics, continuous quality control, efficient workflows and remote quality oversight. In an industry-first move, intelliMaven is a GPT AI application engineered to streamline workflows, deliver on-demand expert feedback, and foster a culture of confidence and autonomy among technologists. The integrated platform delivers a scalable, sustainable quality assurance system tailored for mammography facilities to maximize operational efficiency, optimize compliance with the FDA Mammography Quality Standards Act (MQSA) EQUIP, and meet ACR accreditation standards. The platform empowers facilities to maximize resource allocation and focus on activities that drive the most value.
With iCAD’s AI-enabled ProFound Breast Health Suite, offering clinically proven solutions for cancer detection, density assessment, and personalized risk evaluation, medical professionals will have a more well-rounded set of data on each patient’s breast health. Clinical studies have demonstrated that the use of iCAD’s ProFound AI solutions can significantly improve reading sensitivity and specificity and reduce reading times, thus enhancing clinical decision support and workflow efficiency for radiologists.
“Our partnership with iCAD is a commitment to women’s health that spans the spectrum of breast health care,” said Mo Abdolell, founder and CEO of Densitas. “At the heart of this collaboration is the understanding that mammography is the first line of defense in breast cancer detection. It sets the stage for every decision that follows in the diagnostic, prevention, and treatment pathways. Our operational AI solutions, intelliMammo and intelliMaven GPT AI assistant, together with iCAD’s AI-powered Breast Health Suite elevate the standard for image quality, screening and diagnostic accuracy, and comprehensive care with state-of-the-art AI innovations. This synergy ensures that every woman receives the most precise and personalized care journey possible.”
ProFound Breast Health Suite
ProFound AI offers clinically proven time-saving benefits to radiologists, including reducing reading time by 52.7%, thereby halving the time it takes radiologists to read 3D mammography datasets. ProFound AI for DBT improved radiologist sensitivity by 8% and reduced unnecessary patient recall rates by 7.2%.i The ProFound Riskii platform has a proven track record of predicting the risk of breast cancer 2.4x more accurately in the next year than traditional lifetime risk models.iii,iv iCAD’s ProFound Density Assessment uses mammography images to categorize breast density, leading to personalized patient care plans with supplemental screenings and a custom schedule.
IntelliMammo AI Mammography Quality Platform
IntelliMammo reduces clinical image quality error rates by as much as 44%,v and streamlines compliance with key MQSA EQUIP and adherence to ACR accreditation requirements, quality assurance and oversight tasks in mere seconds and minutes, as opposed to days and weeks. IntelliMaven is designed to increase radiological technologists’ clinical confidence and autonomy, and to limit interruptions to radiologists when reading exams. IntelliMammo densityAI breast density has been clinically validated to have a strong association with breast cancer risk, providing a practical automated method for risk stratification.vi
For more information: www.densitashealth.com
References:
i Conant, E. et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence.
ii ProFound Risk is CE Marked, Health Canada Licensed, and available for investigational use only in U.S.
iii Mikael Eriksson et al. A risk model for digital breast tomosynthesis to predict breast cancer and guide clinical care. Sci. Transl. Med. 14, eabn3971 (2022). DOI: 10.1126/scitranslmed.abn3971
iv Eriksson M, Czene K, Strand F, Zackrisson S, Lindholm P, Lång K, Förnvik D, Sartor H, Mavaddat N, Easton D, Hall P. Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening. Radiology. 2020 Nov;297(2):327-333. doi: 10.1148/radiol.2020201620. Epub 2020 Sep 8. PMID: 32897160.
v Abdolell, M. et al. (2023) Driving mammography image quality improvement using A.I. in Guyana during the Covid-19 pandemic. European Congress of Radiology. Vienna Austria. Poster #C-23808
vi Astley, SM. et al. (2018) A comparison of five methods of measuring mammographic density: a case- control study. Breast Cancer Research
February 18, 2026 
